An observational study in Hemophilia A and Factor VIII (FVIII), sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by University of Texas Southwestern Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 299 studies in Hemophilia A with a site in United States — 40 open to participants now, 59 under way, 17 of them phase 3. Hemophilia A · United States.
Among the 299 studies in Hemophilia A with a site in United States, this one is the 42nd largest by planned enrollment of the 75 observational ones that give a count, is one of 14 that started in 2026, is one of 75 observational ones, reaches primary completion later than 53 of the 58 other live ones, and was the 296th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →40 of the 299 studies in Hemophilia A with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 12–74
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 30–50 · Men only
Hoffmann-La Roche · Sites in United States
Ages 18+ · Men only
Bayer · Sites in United States, Brazil, Canada and 8 more countries
Ages 7–12
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 6 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
299 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 46 · Phase 3 106 · Phase 4 31
First in 1998; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 81 across 310 observational studies indexed under Hemophilia A.
Median enrollment 32 across the 221 interventional studies, 72 across the 75 observational. Of the 220 that completed or were terminated, 109 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
211 of 299 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 2 studies filed under Hemophilia A — fewer than ten, so there is no comparison to draw.
15 of the studies in Hemophilia A with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04644575Phase 3Bioverativ, a Sanofi companyLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | 2027-01-15 |
| NCT05662319Phase 3SanofiA Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia | 2027-03-25 |
| NCT07416526Phase 3Hoffmann-La RocheA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | 2027-09-23 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
Add all 15 to your calendar (.ics) → With an account.
Among the 299 studies in Hemophilia A with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational research study to find out if there is a difference in the way children with moderate or severe hemophilia A, treated on two different types of factor replacement, form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII.
This research study aims to compare the differences in the way children with moderate or severe hemophilia A respond when being treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) vs non-FVIII based replacement therapy (such as Hemlibra) as part of their hemophilia treatment to prevent spontaneous joint bleeds. This study will collect information about the patient's joint health, patient outcomes (using questionnaires), and laboratory testing at specific time points over 3 years.
The study will use an overall approach of comparative effectiveness research (CER) methodology. The investigators plan to recruit participants with severe (FVIII \<1%) and moderate (FVIII 1-4%) HA who take extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy as their clinically prescribed treatment. Both are standard of care treatment for persons with Hemophilia A (PwHA). Using CER principals, this study will analyze differences in 1) hemostatic potential and annualized bleeding rates (Aim 1-3) and 4) joint health (structural and functional) using the Hemophilia Joint Health Score (HJHS) and imaging markers to identify subclinical bleeding and early joint tissue changes in PwHA on novel FVIII and non-FVIII therapies already in use in practice (Aim 4). The proposed study will be the first systematic observational comparative effectiveness study in PwHA on two conventional, standard-of-care novel therapies with differing mechanisms of action to evaluate the overall effectiveness of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study plans to recruit participants with severe (FVIII \<1%) and moderate (FVIII 1-4%) HA.
Drug: Half-life factor VIII based replacement therapy · Drug: Non-FVIII based replacement therapy
Children with moderate or severe hemophilia A being treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) as part of their hemophilia treatment to prevent spontaneous joint bleeds.
Also known as: Altuviiio
Children with moderate or severe hemophilia A being treated with non-FVIII based replacement therapy (such as Hemlibra) as part of their hemophilia treatment to prevent spontaneous joint bleeds.
Also known as: Hemlibra
Thrombin Generation
To determine and compare in vivo thrombin generation parameters; endogenous thrombin potential (ETP) and peak thrombin (PT) for patients on efanesoctocog alfa or emicizumab
Time frame: Thrombin generation assay will be measured at 5 time points within a week of receiving dose of medication
Hemophilia Joint Health Score
To obtain and compare HJHS in patients on efanesoctocog alfa or emicizumab
Time frame: Obtained at baseline and every 6 months, until 3 years
Annualized bleeding rate
To collect bleeding episodes in study participants and to calculate their respective total, treated, and joint annualized bleeding rates
Time frame: From enrollment, every 6 months, until 3 years
Health related quality of life - CHO-KLAT
Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) will be used to evaluate the impact of different treatment strategies. CHO-KLAT will be obtained and compared in study participants on efanesoctocog alfa or emicizumab.
Time frame: From enrollment, every 6 months, until 3 years
Health related quality of life - PedHAL
PedHAL is a validated patient-reported outcome measure designed to assess self-perceived functional abilities in children with hemophilia. PedHAL will be obtained and compared in study participants on efanesoctocog alfa or emicizumab
Time frame: From enrollment, every 6 months, until 3 years
Health related quality of life - CATCH
CATCH (Comprehensive Assessment Tool of Challenges in Hemophilia) is a validated, multi-version patient-reported outcome instrument designed to assess the real-world impact of hemophilia on individuals and their caregivers. CATCH will be obtained and compared in study participants on efanesoctocog alfa or emicizumab
Time frame: From enrollment, every 6 months, until 3 years
Joint Tissue Changes
Point-of-care ultrasound using JADE protocol to evaluate joint tissue changes will be obtained and compared in study participants on efanesoctocog alfa or emicizumab
Time frame: From enrollment, every 6 months, until 3 years
Started Jul 2026 (actual). Primary completion is estimated for May 2033, 82 months after the start.
Of 78 non-industry observational studies under Hemophilia A, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 96. This study's planned 82 months is above that.
Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →